Literature DB >> 2228030

Lymphocyte activation as measured by interleukin-2 receptor expression to gluten fraction 111 in coeliac disease.

I A Penttila1, C E Gibson, B D Forrest, A G Cummins, J T LaBrooy.   

Abstract

Lymphocyte activation was examined by interleukin-2 (IL-2) receptor expression on peripheral blood mononuclear cells from coeliac and control subjects. Purified T cells were incubated with gluten fraction 111 (a known toxic peptide for coeliac subjects), soyabean hydrolysate (an unrelated hydrolysed food antigen), and Concanavalin-A (Con-A, a non-specific mitogen). After 1-5 days incubation, expression of IL-2 receptors was assessed using a cellular enzyme-linked immunosorbent assay (ELISA). Gluten fraction 111 induced expression of IL-2 receptors on T lymphocytes from coeliac but not from normal subjects (P = 0.0005), whereas soyabean hydrolysate did not induce IL-2 receptor expression. Lymphocytes from both coeliac and normal subjects had similar increased IL-2 receptor expression after incubation with Con-A. Flow cytometry was also used to confirm specific expression of IL-2 receptor expression of lymphocytes from coeliac subjects. Interleukin-2 receptor expression increased from 0 to 5.4% of cultured mononuclear cells after 7 days incubation with gluten fraction III. These cells were CD3-positive and CD4-positive. We conclude that peripheral blood lymphocytes from coeliac subjects are sensitized specifically to gluten fraction III.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2228030     DOI: 10.1038/icb.1990.22

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  5 in total

1.  Deficiency of 6B11+ invariant NK T-cells in celiac disease.

Authors:  Randall H Grose; Fiona M Thompson; Adrian G Cummins
Journal:  Dig Dis Sci       Date:  2007-12-13       Impact factor: 3.199

2.  T cell proliferation, MHC class II restriction and cytokine products of gliadin-stimulated peripheral blood mononuclear cells (PBMC).

Authors:  J O'Keeffe; K Mills; J Jackson; C Feighery
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

3.  Serum soluble interleukin-2 receptor, interleukin-6 and tumor necrosis factor alpha as markers of celiac disease activity.

Authors:  Akshay Kapoor; A K Patwari; Praveen Kumar; Anju Jain; Shashi Narayan
Journal:  Indian J Pediatr       Date:  2012-07-06       Impact factor: 1.967

4.  Deficiency of invariant natural killer T cells in coeliac disease.

Authors:  R H Grose; A G Cummins; F M Thompson
Journal:  Gut       Date:  2006-11-24       Impact factor: 23.059

5.  Toward finding the difference between untreated celiac disease and COVID-19 infected patients in terms of CD4, CD25 (IL-2 Rα), FOXP3 and IL-6 expressions as genes affecting immune homeostasis.

Authors:  Nastaran Asri; Ehsan Nazemalhosseini Mojarad; Hamed Mirjalali; Seyed Reza Mohebbi; Kaveh Baghaei; Mohammad Rostami-Nejad; Abbas Yadegar; Mostafa Rezaei-Tavirani; Hamid Asadzadeh Aghdaei; Kamran Rostami; Andrea Masotti
Journal:  BMC Gastroenterol       Date:  2021-12-11       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.